Here you'll find several resources to help start appropriate patients
on XOLAIR and offer continued support.
PHYSICIAN LOCATOR
The Physician Locator is an online listing of healthcare providers who may
treat moderate to severe persistent allergic asthma. Here you can:
NURSE CHECKLIST
Once a patient has been identified as an appropriate candidate for XOLAIR
and has been prescribed XOLAIR by a physician, follow these 6 easy
steps to ensure
a smooth transition onto treatment.
Check
out the Checklist
More than 100,000 patients have been prescribed since the launch of
XOLAIR
The XOLAIR Physician Locator is for informational use only.
Genentech and Novartis do not endorse the use of nor provide
recommendations or referrals of any physicians included in the XOLAIR
Physician Locator. Genentech and Novartis make no representations or
warranties of any kind with respect to the information obtained
through the XOLAIR Physician Locator, including without limitation,
the implied warranties of merchantability and fitness for any
particular purpose. Your selection of a physician is your sole
responsibility, and Genentech and Novartis shall in no event be liable
to you or to anyone for any decision made or action taken by you in
the reliance on information provided in the XOLAIR Physician Locator.
Any communications you have with a listed physician are your
responsibility and are not subject to the Privacy Policy of this site.
By using the XOLAIR Physician Locator, you agree to these terms and
conditions.
INDICATION
XOLAIR® (omalizumab) for subcutaneous use is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.
|
Important Limitations of Use
|
|
|
|
 |
XOLAIR is not indicated for treatment of other allergic conditions |
|
|
|
XOLAIR is not indicated for the relief of acute bronchospasm or
status asthmaticus |
|
|
|
XOLAIR is not indicated for use in pediatric patients less than
12 years of age |
IMPORTANT SAFETY INFORMATION
|
WARNING: Anaphylaxis
Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur (see Warnings and Precautions: Anaphylaxis).
|
|
|
|
XOLAIR should only be administered in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening. |
|
|
|
XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR (see Warnings and Precautions). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction. |
|
|
|
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders. |
|
|
|
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus. |
|
|
|
A constellation of signs and symptoms including arthritis/arthralgia, rash (urticaria or other forms), fever and lymphadenopathy similar to serum sickness have been reported in post-approval use of XOLAIR in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms. |
|
|
|
Patients should be given and instructed to read the accompanying Medication Guide before starting treatment and before each subsequent treatment. |
|
|
|
Do not abruptly discontinue corticosteroid use upon initiation of XOLAIR therapy. Decrease corticosteroids gradually under the direct supervision of a physician. |
|
|
|
In patients ≥12 years of age, the most commonly observed adverse reactions (>1% more frequent in XOLAIR-treated patients) from 4 placebo-controlled asthma studies were arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%). |
|
|
|
The adverse events most frequently resulting in clinical intervention (e.g. discontinuation of XOLAIR, or the need for concomitant medication to treat an adverse event), in either placebo-controlled or other controlled asthma studies, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients. |
|
|
